Your browser doesn't support javascript.
loading
Lack of efficacy of a partial adenosine A1 receptor agonist in neuropathic pain models in mice.
Metzner, Katharina; Gross, Tilman; Balzulat, Annika; Wack, Gesine; Lu, Ruirui; Schmidtko, Achim.
Afiliação
  • Metzner K; Institute of Pharmacology and Clinical Pharmacy, Goethe University Frankfurt, 60438, Frankfurt am Main, Germany. metzner@em.uni-frankfurt.de.
  • Gross T; Institute of Pharmacology and Clinical Pharmacy, Goethe University Frankfurt, 60438, Frankfurt am Main, Germany.
  • Balzulat A; Institute of Pharmacology and Clinical Pharmacy, Goethe University Frankfurt, 60438, Frankfurt am Main, Germany.
  • Wack G; Institute of Pharmacology and Clinical Pharmacy, Goethe University Frankfurt, 60438, Frankfurt am Main, Germany.
  • Lu R; Institute of Pharmacology and Clinical Pharmacy, Goethe University Frankfurt, 60438, Frankfurt am Main, Germany.
  • Schmidtko A; Institute of Pharmacology and Clinical Pharmacy, Goethe University Frankfurt, 60438, Frankfurt am Main, Germany.
Purinergic Signal ; 17(3): 503-514, 2021 09.
Article em En | MEDLINE | ID: mdl-34313915
ABSTRACT
Previous studies suggest that adenosine A1 receptors (A1R) modulate the processing of pain. The aim of this study was to characterize the distribution of A1R in nociceptive tissues and to evaluate whether targeting A1R with the partial agonist capadenoson may reduce neuropathic pain in mice. The cellular distribution of A1R in dorsal root ganglia (DRG) and the spinal cord was analyzed using fluorescent in situ hybridization. In behavioral experiments, neuropathic pain was induced by spared nerve injury or intraperitoneal injection of paclitaxel, and tactile hypersensitivities were determined using a dynamic plantar aesthesiometer. Whole-cell patch-clamp recordings were performed to assess electrophysiological properties of dissociated DRG neurons. We found A1R to be expressed in populations of DRG neurons and dorsal horn neurons involved in the processing of pain. However, administration of capadenoson at established in vivo doses (0.03-1.0 mg/kg) did not alter mechanical hypersensitivity in the spared nerve injury and paclitaxel models of neuropathic pain, whereas the standard analgesic pregabalin significantly inhibited the pain behavior. Moreover, capadenoson failed to affect potassium currents in DRG neurons, in contrast to a full A1R agonist. Despite expression of A1R in nociceptive neurons, our data do not support the hypothesis that pharmacological intervention with partial A1R agonists might be a valuable approach for the treatment of neuropathic pain.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor A1 de Adenosina / Agonistas do Receptor A1 de Adenosina / Neuralgia Limite: Animals Idioma: En Revista: Purinergic Signal Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptor A1 de Adenosina / Agonistas do Receptor A1 de Adenosina / Neuralgia Limite: Animals Idioma: En Revista: Purinergic Signal Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha
...